Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Press release, Helsinki, 23 March 2026 at 1 PM (EET)
Nexstim’s NBS System 6 gains FDA clearance for treatment of Adolescent Depression
Nexstim Plc ("Nexstim" or "Company") announces the launch of the NBS 6 system for the treatment of Major Depressive Disorder (MDD) in adolescent patients, 15 to 21 years of age, in the United States.
In the United States, The Nexstim Navigated Brain Stimulation (NBS) 6 System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and also as an adjunct for the treatment of MDD in adolescent patients, 15 to 21 years of age. The NBS 6 is also indicated as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). For use in diagnostics, the NBS 6 is FDA-cleared for pre-surgical mapping of the speech and motor cortices of the brain.
The NBS 6 is a new product generation that enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this system is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.
Nexstim announced the release of the NBS 6 for therapy applications in 2023, and for diagnostic applications in October 2025.
Mikko Karvinen, CEO of Nexstim, comments: “We are happy to announce that MDD treatments with Nexstim’s navigated TMS are now available also for younger patients in the United States. Part of our strategy is to expand into new indications, and we have found adolescent depression an expansion opportunity that will bring value to patients and customers while supporting our business objectives.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com